Učitavanje...
Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC)
Recently, the standard of care for metastatic Castration Resistant Prostate Cancer (mCRPC) has changed considerably. Persistent androgen receptor (AR) signaling has been identified as a target for novel therapies and reengages the fact that AR continues to be the primary target responsible for metas...
Spremljeno u:
| Glavni autori: | , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BioMed Central
2014
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4167156/ https://ncbi.nlm.nih.gov/pubmed/25062956 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2490-14-55 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|